

Pfizer Oncology: Who We Are and What We Do



One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find cures for these deadly diseases.


OUR IMPACT

 **23** innovative cancer medicines and biosimilars, treating **30** types of cancer.

 **11** FDA Breakthrough Therapy Designations since **2013**.

 **up to 12** potential approvals expected before the end of **2025**.

OUR SCIENCE

 **130** ongoing clinical trials with a Pfizer oncology medicine.

 **8,500+** active participants in ongoing Pfizer-sponsored oncology clinical trials.


Innovative Modalities to Drive Potential Future Therapies




Monoclonal Antibodies (mAbs)
Act like human antibodies in the immune system to target cancer cells.



Bispecifics
Bring cancer and immune cells together, causing an immune response that attacks the cancer.



Antibody-drug Conjugates (ADCs)
Deliver chemotherapy or a radioactive particle directly to cancer cells.



Cancer Vaccines
Introduce antigens that trigger an immune response.



Small Molecules
Pass through cell membranes to reach targets within cancer cells.

OUR AREAS OF FOCUS

Breast Cancer
Revolutionizing standards of care across multiple subtypes and stages.



Genitourinary Cancer
Leveraging a 15-year legacy to advance treatment for pervasive and hard-to-treat cancers.



Colorectal Cancer
Targeting the aggressive biology of *BRAF* + metastatic colorectal cancer.



 **Blood Cancer**
Changing the treatment landscape for rare, life-threatening cancers.



Lung Cancer
Advancing biomarker-driven therapies for the leading cause of cancer-related death.



Melanoma
Delivering a precision medicine for mutation-driven, advanced melanoma.



Biosimilars
Improving patient access to essential medicines.

We've made meaningful progress – but our work is far from finished. Millions of people are living with cancer, and millions more will receive a diagnosis in the future. They are the reason we will continue to work tirelessly to deliver on our purpose:

BREAKTHROUGHS THAT CHANGE PATIENTS' LIVES.™

Intended for use with media professionals only. This document includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information can be found in Pfizer's filings with the U.S. Securities and Exchange Commission, including Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and subsequent reports on Form 10-Q, which are available at www.sec.gov and www.pfizer.com.

